MPAM
AGIO icon

Monarch Partners Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Monarch Partners Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$1.64M Buy
58,246
+426
+0.7% +$12K 0.48% 103
2022
Q3 		$1.64M Buy
+57,820
New +$1.55M 0.49% 101

Other funds holding AGIO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Monarch Partners Asset Management's AGIO Position: Q4 2022 in Review

Monarch Partners Asset Management increased its Agios Pharmaceuticals (AGIO) stake by 0.74% in Q4 2022, buying an estimated $12K and bringing the position to 58,246 shares worth $1.64M. The position accounts for 0.48% of the portfolio, ranked #103.

Monarch Partners Asset Management first reported a position in AGIO in Q3 2022 and has held it in 2 quarters since. 159 funds tracked by Wall St. Rank hold AGIO as of Q4 2022.

  • Monarch Partners Asset Management held 58,246 shares of Agios Pharmaceuticals worth $1.64M as of Q4 2022.
  • Monarch Partners Asset Management bought 426 Agios Pharmaceuticals shares in Q4 2022, an estimated $12K.
  • Agios Pharmaceuticals made up 0.48% of Monarch Partners Asset Management's portfolio in Q4 2022, its #103 holding.
  • Monarch Partners Asset Management first reported a position in Agios Pharmaceuticals in Q3 2022 and has held it in 2 quarters since.
  • 159 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2022.

Based on Monarch Partners Asset Management's 13F filing for Q4 2022, filed 2 Feb 2023.